Long‐term outcomes of proton therapy for prostate cancer in Japan: a multi‐institutional survey of the Japanese Radiation Oncology Study Group. (14th February 2018)

• Record Type: Journal Article
• Authors: Iwata, Hiromitsu; Ishikawa, Hitoshi; Takagi, Masaru; Okimoto, Tomoaki; Murayama, Sigeyuki; Akimoto, Tetsuo; Wada, Hitoshi; Arimura, Takeshi; Sato, Yoshitaka; Araya, Masayuki; Mizoe, Jun‐etsu; Gosho, Masahiko; Nakamura, Katsumasa; Shirato, Hiroki; Sakurai, Hideyuki
• Is Part Of: Cancer medicine. Volume 7:Number 3(2018:Mar.)
• Page Start: 677
• Page End: 689
• Publication Date: 2018-02-14
• Subjects: Biochemical relapse‐free survival -- late toxicity -- multi‐institutional survey -- prostate cancer -- proton therapy; 616.994005
• DOI: 10.1002/cam4.1350
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: This is the first multi‐institutional retrospective survey of the long‐term outcomes of proton therapy (PT) for prostate cancer in Japan. This retrospective analysis comprised prostate cancer patients treated with PT at seven centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The NCCN classification was used. Biochemical relapse was based on the Phoenix definition (nadir + 2.0 ng/mL). Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0. There were 215, 520, and 556 patients in the low‐risk, intermediate‐risk, and high‐risk groups, respectively. The median follow‐up period of surviving patients was 69 months (range: 7–107). Among all patients, 98.8% were treated using a conventional fractionation schedule and 1.2% with a hypofractionation schedule; 58.5% and 21.5% received neoadjuvant and adjuvant androgen deprivation therapy, respectively. The 5‐year biochemical relapse‐free survival (bRFS) and overall survival rates in the low‐risk, intermediate‐risk, and high‐risk groups were 97.0%, 91.1%, and 83.1%, and 98.4%, 96.8%, and 95.2%, respectively. In the multivariate analysis, the NCCN classification was a significant prognostic factor for bRFS, but not overall survival. The incidence rates of grade 2 or more severe late gastrointestinal and genitourinary toxicities were 4.1% and 4.0%, retrospectively. This retrospective analysis of a multi‐institutional survey suggested that PT is effective and well‐tolerated for prostate cancer. Based on this result, a multi‐institutional prospective clinical trial (UMIN000025453) on PT for prostate cancer has just been initiated in order to define its role in Japan. Abstract : The retrospective analysis of a multi‐institutional survey in Japan suggested that proton therapy for localized prostate cancer demonstrates favorable biochemical control with low incidences of late toxicities. Based on the present results, a multi‐institutional prospective clinical trial that involving all participating Japanese proton therapy centers has just been started in order to determine its role in the treatment of prostate cancer.